Jasper Therapeutics ( NASDAQ: JSPR ) added ~30% pre-market Friday after announcing new data from a Phase 1 trial designed to evaluate its lead candidate briquilimab in a combination therapy for older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
The company said the data would be part of a presentation at an upcoming medical meeting in Orlando, Florida.
The trial tested briquilimab in combination with cancer therapy fludarabine and low-dose irradiation (Flu/TBI) conditioning. The patients aged 62 – 79 had acute AML or MDS and were undergoing allogeneic hematopoietic cell transplants.
According to data, briquilimab was safe, well-tolerated, and led to durable remissions in 8 of 12 of the first treated AML patients, Jasper ( JSPR ) said, noting that all eight patients were relapse-free at one-year follow-up.
29 AML and MDS patients who received the combination therapy were also found to have lower than expected rates of acute and chronic graft-versus-host disease (GVHD).
Another data set showed the cost-benefit of briquilimab plus Flu/TBI among 12 patients who received outpatient conditioning and donor cell transplants at a single study center. During the first 100 days following the procedure, the group was found to have seven hospitalizations with a mean hospital stay of 4 days.
“….we believe these data demonstrate that briquilimab is an agent that can markedly improve the safety and efficacy of stem cell transplants for a wide range of malignant and rare diseases,” Chief Executive Officer of Jasper ( JSPR ) Ronald Martell noted.
The readout comes days after the company announced plans to reprioritize its research efforts on briquilimab.
For further details see:
Jasper climbs 30% on new Phase 1 data for lead asset in blood cancer